Replies to post #106679 on Biotech Values

[iwfal]

I thought your assertions were questionable because no one in the HCV arena whose opinion I respect thinks that a mere two-drug cocktail will be able to get the job done.

Thanks. Ok - for the record, the reason I think it is pertinent to the valuation of IFN-L is the magnitude of the failure. No breakthroughs in combo with SOC. 55% breakthrough wo SOC. If it had been a 20% difference... or if it had been a combo of weak DAAs (as opposed to using an NS5A - the great hope of DAAs) or ... I'd have not ascribed as much incremental increase in IFN-L value.

Question - Is there any value of SVR in the T+VX222 trial (in G1 naive patients) below which you would start to question the chances of a 3 drug DAA (wo SOC) taking over 90% of the market? <20%? <10%? ...